Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Key Inclusion Criteria:

Completed the full study treatment period of 52 weeks in preceding phase III studies, and
have been receiving secukinumab treatment during the maintenance phase of the preceding
phase III studies, and show at least a partial response (PASI 50 or better) at Week 52 of
the preceding phase III studies.

Written informed consent form.

Key Exclusion Criteria:

A protocol deviation in either of the preceding phase III studies which according to the
investigator prevented the meaningful analysis of the extension study for the individual
subject.

Ongoing use of prohibited psoriasis or non-psoriasis treatments.

Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female
after conception and until the termination of gestation, confirmed by a positive hCG
laboratory test (>10 mIU/mL).

Women of child-bearing potential, defined as all women physiologically capable of becoming
pregnant, unwilling to use effective contraception during the study and for 16 weeks after
stopping treatment.